Mark Fendrick, MD, thinks that right now, the relative accuracy of blood-based tests for CRC compared with available alternatives is not quite comparable. He explains.
With a population goal of having 80% to 90% of age-eligible Americans screened for colorectal cancer, colonoscopy can not be the initial test for everyone, Fendrick emphasizes.
Your daily dose of the clinical news you may have missed.
Never considered the carbon footprint left by a screening for colorectal cancer? Fendrick has and did the research to learn more. He explains in this short video.
GLP-1 receptor agonists showed promise in lowering obesity-related cancer risks in adults with type 2 diabetes, particularly colorectal cancer.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Results showed that a nanoencapsulated CBD cream reduced UV-A–induced nuclear and mitochondrial DNA damage linked to photoaging in human skin.
Your daily dose of the clinical news you may have missed.
An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.